Thu, 22 Oct 2026
Markets
DJIA 44,210.31 +0.42% S&P 500 6,204.88 +0.31% NASDAQ 20,398.05 -0.18% RUSSELL 2000 2,271.14 +0.55% FTSE 100 8,786.20 -0.09% DAX 24,120.40 +0.26% NIKKEI 225 39,986.30 +1.02% HANG SENG 24,072.30 -0.44% US 10-YR 4.281% -0.03 CRUDE OIL $67.41 +0.68% GOLD $3,342.10 +0.21% BTC $61,845 -1.12% EUR/USD 1.1782 +0.14% DJIA 44,210.31 +0.42% S&P 500 6,204.88 +0.31% NASDAQ 20,398.05 -0.18% RUSSELL 2000 2,271.14 +0.55% FTSE 100 8,786.20 -0.09% DAX 24,120.40 +0.26% NIKKEI 225 39,986.30 +1.02% HANG SENG 24,072.30 -0.44% US 10-YR 4.281% -0.03 CRUDE OIL $67.41 +0.68% GOLD $3,342.10 +0.21% BTC $61,845 -1.12% EUR/USD 1.1782 +0.14%
Claude did not invent scorpion antivenom

Claude did not invent scorpion antivenom

An investment research firm wanted to prove AI could revolutionize drug development. So they teamed up with Anthropic to see whether an unreleased version of Claude could make scorpion antivenom. It couldn't. It came up with some promising starting points, but nothing close to an actual drug, expert...

A scorpion

An investment research firm wanted to prove AI could revolutionize drug development. So they teamed up with Anthropic to see whether an unreleased version of Claude could make scorpion antivenom. It couldn't. It came up with some promising starting points, but nothing close to an actual drug, experts tell The Verge.

Citrini Research, the firm behind the experiment, admitted that "none of us could claim to know anything about AI as it related to biology." That didn't stop it from trying to make a drug from scratch - or publishing a blog post titled "We Wanted to Use Claude to Create a New Drug. Here's What Happened." The account came comple …

Read the full story at The Verge.